Total number
Full text
Total number
Full text
Number of local repositories
Full text
0216U003545,
0113U002315
,
Study of the molecular-genetic mechanisms of resistance to the tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and reasoning of resistance overcoming ways
Dyagil I.S., Minchenko J.M.,
01-02-2016
State institution "National research centеr for radiation medicine of the National academy of medical sciences of Ukraine "
The object of study - patients with chronic myeloid leukemia, primary and secondary resistant to tyrosine kinase inhibitor therapy. The aim - to determine the main molecular genetic mechanisms of primary and secondary resistance to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia, to justify the ways of resistance overcoming and increasing of treatment efficiency. Research Methods - hematologic, cytogenetic, molecular genetic, immunogenetic, cultural and statistics. The results of research. The study involved 154 patients with CML. Among them, 102 - with primary and 52 - with secondary resistance to imatinib treatment. It was found that primary resistance was defined mainly in CML patients pretreated during more than 6 months. The vast majority of patients with primary and secondary resistance had intermediate and high risk prognostic Sokal index. These patients did not achieve a complete cytogenetic and major molecular response in the expected time frame. Additional clonal chromosomal abnormalities (mostly extra Ph-chromosome) was present in 10% of primary resistant patients at diagnosis. It was found that patients with e14a2 transcript respond better to treatment with imatinib. The best event-free survival, and a lower incidence of secondary resistance were shown for these patients. CML patients, primary and secondary resistant to imatinib, with the marker mutations (G250E, Y253F / H, T315I, F359I) need to be switched on the 2nd generation of tyrosine kinase inhibitors or use of allogenic hematopoietic stem cell transplantation. The connection of pretreatment time with the appearance of BCR/ABL1 mutations. Patients achieved major molecular response, developed the secondary resistance later in comparison with patients who achieved only a complete cytogenetic response. It is shown that the level of BCR/ABL1 ? 0,1% causes a high probability of stable molecular remission for at least the next year. Exceeding of BCR/ABL1 level in 0.1 % increases the probability of loss of complete cytogenetic response. It was revealed that the secondary resistance to imatinib therapy was more frequent in CML patients with radiation exposure in anamnesis compared to the group of non-irradiated patients. It was found that the allele HLA-DRB1*12 is an optional marker of the risk of the secondary resistance to TKI therapy in CML patients. The carriage of the allele HLA-A*68, HLA-B*15, HLA-B*40, DQB1*0304 and DQB1*0604 reduces the risk of secondary resistance. High levels of pro-inflammatory IL-8, anti-inflammatory IL-4 and IL-10 and low concentrations of IL-2 and IFN-gamma in peripheral blood serum during CML diagnosis increased the risk of resistance development. Increasing concentration of proinflammatory interleukins IL-4 and IL-10 was determined in patients with secondary resistance. High proliferative capacity of hematopoietic and bone marrow stromal cells was revealed in patients with CML with resistance to imatinib treatment. A set of prognostic factors of primary and secondary resistance in CML patients was designed. Ways to overcome the primary and secondary resistance were offered. Recommendations to improve the effeciency of TKI therapy were made. The algorithm of molecular monitoring of CML patients with primary and secondary resistance was developed.
Балан Валентина Володимирівна
Дмитренко Ірина Віталіївна
Дмитренко Олена Олександрівна
Любарець Тетяна Федорівна
Малінкіна Тетяна Володимирівна
Парамонов Віктор Володимирович
Товстоган Анжела Олександрівна
Федоренко Віра Григорівна
Шляхтиченко Тетяна Юрівна
Шолойко Валентина Василівна
2020-04-02
Updated: 2025-12-21
Saving a scientific data set occurs in two stages:
1.) Creating a data set
Enter the name of the set, a brief description of the set (annotation), and click the “Create set” button. After that, a draft data set will be automatically created, which you can save for further work with the set. The system will redirect you to the “Data set information” page.
2.) Filling in the data
On the “Data set information” page, you need to fill in all the fields related to the data set and upload the files.
Please note! Each file is uploaded separately. This is done to ensure the stable operation of the system.
Once you have filled in the information about the scientific data set and added the necessary files, you can save the draft or send the data to the system.
Please note! Once the data has been sent, you cannot change it.
Drafts are necessary for storing the data set and editing it before sending.
All accounts on the NRA website go through a standard registration procedure and are verified. However, in order to obtain additional features, such as publishing open reviews of academic texts, verification by affiliation is required.
To obtain the status “verified”, you must change your primary email address to a corporate one, which is tied to a scientific or educational institution.
For example: user@ukrintei.ua, user@nas.gov.ua
After confirming your corporate email address, your account will be automatically verified by affiliation.
If your email address is corporate, but your account does not have a verification mark, you need to write to us at the email address NRAT@ukrintei.ua. After verification, we will add your address to the database, and your account will be verified.
After completing the verification procedure for affiliation, you can change the primary email address to a convenient one for you, without losing your status during the current verification.
You only need to verify for affiliation once.
* We use corporate addresses from the Unified State Database on Education and the State Register of Scientific Institutions Supported by the State
To search for news published on the official website of NRАT in the “News” section, you need to enter one word, several words, or an exact phrase in the search field. Different terms are separated by spaces.
The search is performed everywhere – in the title and the news text.
For a more comprehensive result, it is recommended to use word stems (parts of words without endings).
When using multiple words for the search, they are combined using one of the logical methods described below.
By default, the logical connector “and” is used. In this case, search results will include all news releases that contain the specified words, even if they are located separately from each other and are in different parts of the text.
Example: Search phrase: OECD report. Search result: all news containing the words “report” and “OECD” in the text and in the title, both together and separately.
If a phrase or phrase is enclosed in quotation marks (“), the results will include all publications where this exact phrase or phrase is found.
Example: Search phrase: “OECD report.” Search result: all news containing the exact phrase “OECD report.”
If you know the publication date of the news or are interested in a specific time frame in which they were published on the website, you can select such a date or date range in the additional field that looks like a calendar. The date is entered in the format year-month-day and confirmed by clicking on the corresponding date in the calendar dropdown. You can enter a date or choose one by browsing through the calendar by months and years. By default, the interval starts from the oldest date (2018-01-23) and ends with the current date.
You can also use one or more hashtags, which are located under the search field on the right side of the “News” page.
Please note: The search for academic texts is carried out in a separate search window at the following link https://nrat.ukrintei.ua/searchdb.
